CHO Stable Cell Line Development

Curia provides stable CHO cell line development services for diagnostic or therapeutic products.

Developed from the CHO-K1 parental cell line, Curia offers the CHO-GSN™ stable cell line expression platform for the production of proteins and antibodies. CHO-GSN™ is a glutamine synthetase (GS) knockout cell line for the generation of a research cell bank (RCB) and future use as a manufacturing cell line for commercial products. With multiple RCBs used for programs at the clinical stage, this platform offers clients a cell line with lineage documentation and a commercial use license for commercialization (royalty-free option available).

Curia provides the CHO-GSN™ platform as a CHO stable cell line development service using its proprietary knockout cell line, custom stable expression vectors, and glutamine synthetase (GS) selection technology platform.

CHO-GSN Parental Cells Proprietary Stable Expression Vectors Proprietary Stable Cell Line Generation Know-how
  • CHO-K1 GS knockout
  • Suspension adapted
  • Animal product-free culturing
  • Compatible with chemically defined commercial media
  • Path to commercialization
  • High expression stable expression vectors
  • Bicistronic vectors for antibodies
  • Monocistronic vectors for proteins
  • Vectors for 3+ chain molecules available
  • Proprietary methods for cell line development & stable pool selection
  • Experience in selecting and maintaining stability
  • Animal component-free culturing
  • Compatible with chemically defined commercial media

As a service, RCBs are generated under the following workflow:

Stable Vector Construction Stable Pool Generation Stable Clone Generation Stable Subclone Generation
Curia Proprietary Stable Expression Vectors

  • Custom designed for CHO-GSN platform
  • Non-CMV promoters
  • Thorough QC & sequence confirmation
CHO-GSN Platform

  • CHO-GSN parental cells
  • CHO-K1 derived
  • MaxCyte Electroporation
  • MSX as high selection press
CHO-GSN High Titer Clones

  • CHO-GSN cells
  • High titer clones obtained without intensive screening
  • Option to apply the Ambr15
CHO-GSN Monoclonal Cell Line

  • CHO-GSN cells
  • Second round allows for obtaining monoclonality proof without compromising risk of loss of high yield (during clone generation)
  • Use of Solentim Cell Metric for confirmation of monoclonality

Final Research Cell Banks

  • High titer clones selected
  • Monoclonality ensured
  • Tolerance to shear force and other bioreactor conditions tested

After the RCB is developed, Curia also offers characterization services, MCB generation, and process development services:

  • Comprehensive Protein Characterization
  • Generational Stability Study
  • Gene Copy Number Determination
  • Master Cell Bank Generation
  • Upstream, downstream, analytical development, and formulation development

Download flyer: Large-scale Ab Production: Hybridoma or Recombinant?
Download brochure: GMP production of antibodies & proteins for critical assays and diagnostic applications – From Development to Manufacturing in 100 days